MM+M
Trinity’s Krista Perry, Partner & Head of Launch Excellence, was featured in an article by MM+M titled, “How to achieve a successful drug launch.” Read the article to learn more about what factors contribute to a successful drug launch. Read Now…
Drug Discovery Today
Trinity’s Lisa Bailey, Ph.D., Managing Director of Insights & Head of DEI Strategy, authored an article that was published in Drug Discovery Today. Read the article, “The Challenges and Opportunities in Clinical Trial Diversity: Mistrust in the healthcare system is a significant barrier to recruitment,” to learn more. Read Now…
Fierce Pharma
Trinity’s Krista Perry, Partner & Head of Launch Excellence, was featured in an article by Fierce Pharma to discuss our latest white paper, Moving the Needle: Lessons from the 2023 Launch Class. Read the article to learn more about what factors contribute to a successful drug launch. Read Now…
The Pharma Letter
Trinity Life Sciences’ recent white paper on the first year performance of the 2023 launch class was featured in an article published on The Pharma Letter. Read Now…
Pharmaceutical Market Europe
Trinity’s recent white paper, Picking Winners: Portfolio Management for a New Era, was mentioned in a recent article by Pharmaceutical Market Europe. Read Now…
The Pharma Letter
The biopharma industry is intensely competitive, and companies must go to great lengths to gain any commercial edge. However, it is also an industry that sees more failure than success. Leslie Orne, President & CEO of Trinity Life Sciences, provides an expert view in The Pharma Letter on how biopharma companies can make the best choices to achieve commercial success. Read Now…
MM+M Podcast
Trinity Life Science’s Monica Martin De Bustamante analyzes the Medicare-negotiated prices of the first 10 drugs under the Inflation Reduction Act. Listen Now…
Boston Business Journal
Check out Nancy Phelan’s profile in the Boston Business Journal. Read Now…
Pharmaceutical Executive
It’s clear that there is still work to be done with regard to diversity in clinical trials. Lisa Bailey, Managing Director and Head of DEI Strategy at Trinity Life Sciences, shares her insights with Pharmaceutical Executive on the lack of diversity in trials and how the industry can work to solve this problem. Read Now…
MedCity News
“While FDA approval has long been a singular prize, companies should also mine their assets for the strongest commercial opportunities. …the ability to take a drug to market is an important milestone, but it is not the entire picture. To truly move the needle, both clinically and commercially, biopharma companies must fine-tune their teams, approaches and incentives to produce unique and innovative products.”Read more from Leslie Orne’s new op-ed in MedCity News entitled, “Balancing Risk and Opportunities to Choose Winning…
